ArticleTherapeutic advances in drug safety2026
Medication-related nephrotic syndrome: a real-world study from 2004 to 2024 based on the Food and Drug Administration Adverse Event Reporting System.
Article in Therapeutic advances in drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nephrotic syndrome is a clinical syndrome caused by glomerular injury. Medication-related nephrotic syndrome (MRNS) has become an important focus of pharmacovigilance. However, there is currently a lack of real-world studies on MRNS in large populations. Objectives: To systematically evaluate adverse drug events associated with MRNS using the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and to identify high-risk medications and their onset characteristics. Design: A retrospective pharmacovigilance study based on disproportionality analysis and Bayesian signal detection. Methods: This is a retrospective pharmacovigilance study. FAERS reports from 2004 to 2024 were extracted, cleaned, and standardized to identify MRNS cases. The association between medications and MRNS was evaluated using four methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio, Multi-Item Gamma Poisson Shrinker (MGPS), and Bayesian Confidence Propagation Neural Network (BCPNN). In addition, medication risk classification and cumulative risk curve of medication-induced onset time were conducted. Results: A total of 3990 MRNS cases were identified, including 1963 males (56.23%) and 1528 females (43.77%). Fifty-four medications demonstrated significant positive signals, including 26 antineoplastic medications (ramucirumab, ROR = 33.59), 7 anti-inflammatory medications (sulfasalazine, ROR = 24.74), 2 digestive system medications (famotidine, ROR = 29.28), and 19 other medications (phentermine, ROR = 41.76). BCPNN values indicated that phentermine (5.37), penicillamine (5.13), and ramucirumab (5.06) posed the highest risk. Onset-time analysis showed the shortest average onset for anticancer agents (120.98 days) and the longest for anti-inflammatory medications (165.12 days). Conclusion: This study provides the first large-scale evaluation of MRNS using FAERS. By identifying high-risk medications and characterizing onset-time patterns, these findings offer valuable evidence for early risk recognition and may support improved pharmacovigilance strategies to reduce medication-related kidney injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.